Amardeep Sodhi, MD
Infectious Disease · Peoria, AZNPI 1366406464
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,034 of the $10,236 with a category attached, or 78.5%. 22 manufacturers reported payments, led by Insmed, Inc. at 29.0% of the total. Reporting peaked in 2020 at $2,637 and has fallen 64.9% since, to $925 in 2025. Among infectious disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 489 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$3K
- Viiv Healthcare Company$2K
- Gilead$2K
- Merck$1K
- AbbVie$472
- Astellas Pharma US Inc$396
- plus $2K from 16 others
What the payments were for
- Consulting fees$1,50015%
- Food & beverage$8,03478%
- Education$7017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 84 | $2,964 |
| Viiv Healthcare Company | 115 | $1,717 |
| Gilead | 82 | $1,524 |
| Merck | 75 | $1,106 |
| AbbVie(2 entities) | 14 | $472 |
| Astellas Pharma US Inc | 12 | $396 |
| Paratek Pharmaceuticals, Inc. | 31 | $366 |
| Melinta Therapeutics, LLC | 13 | $347 |
| Shionogi Inc | 14 | $315 |
| Janssen Products, LP | 2 | $185 |
| Theratechnologies Inc. | 9 | $166 |
| Johnson & Johnson(2 entities) | 2 | $140 |
| Mayne Pharma Commercial LLC | 10 | $138 |
| Napo Pharmaceuticals Inc | 7 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $88 |
| AstraZeneca | 6 | $85 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Advanced Oxygen Therapy Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,236 in reported general payments places this provider in the 90th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 68 | $1,012,485 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 155 | $676,731 |
| DovatoDolutegravir Sodium/Lamivudine | 36 | $121,397 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 30 | $118,905 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 20 | $95,160 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $91,845 |
| TivicayDolutegravir Sodium | 26 | $59,345 |
| Fluconazole | 71 | $11,678 |
| Ethambutol Hcl | 66 | $6,523 |
| ErtapenemErtapenem Sodium | 16 | $6,504 |
| Vancomycin Hcl | 41 | $5,895 |
| Voriconazole | 13 | $5,601 |
| Rifampin | 48 | $3,413 |
| Itraconazole | 16 | $3,122 |
| CefoxitinCefoxitin Sodium | 11 | $2,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $2,964 | $1,012,48568 claims |
| GileadBiktarvy, Genvoya | $1,524 | $795,635185 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay | $1,717 | $272,58687 claims |
| Janssen Products, LPSymtuza | $185 | $95,16020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 146 infectious disease providers in Arizona.
Other infectious disease in Peoria
- Thanes VanigPhoenix$258K
- Anita KohliChandler$213K
- Vipul GanatraPhoenix$151K
- Jorge MeraNogales$101K
- Ana MoranPhoenix$35K
- Robert OrensteinPhoenix$26K
- Edward CachayScottsdale$26K
- Aman DalalScottsdale$22K
- Adriana GaidiciPhoenix$20K
- Dwight ClarkePhoenix$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.